Jorge Reis-Filho
As the Chief of AI for Science Innovation, I lead a team dedicated to accelerating drug discovery and transforming clinical development in oncology and biopharmaceuticals R&D. Our focus is to achieve this through the development and implementation of innovative, impactful AI solutions that are reusable at scale. We are using frontier AI solutions to power advanced foundation models and agentic frameworks, as well as building potentially transformational new technologies aligned to AstraZeneca's bold ambitions. These technologies could be strategically crucial in the development of next-generation therapies that have the potential to improve patients’ lives.
My previous roles within AstraZeneca include the Chief AI and Data Scientist, Oncology R&D and Vice President of Cancer Biomarker Development. In these roles, I spearheaded the development and deployment of multimodal foundation models, advanced data science approaches, and agentic AI frameworks to drive innovation throughout the company’s oncology pipeline and portfolio. This included the creation and clinical validation of novel biomarkers, which significantly enhanced our ability to select treatments and therapeutic combinations tailored precisely to each patient’s clinical journey.
With a background in molecular pathology, bioinformatics, functional genomics, and artificial intelligence, I joined AstraZeneca in 2023 as the VP of Cancer Biomarker Development. In this role, I led teams dedicated to developing and meticulously validating mechanistically informed yet clinically deployable biomarkers for patient selection and prediction of therapy response. Key innovations included the Quantitative Continuous Scoring (QCS) computational pathology biomarkers, as well as pioneering approaches leveraging ctDNA and proteomics to guide clinical decision-making and enhance therapeutic outcomes.
Prior to joining AstraZeneca, I served as the Chief of Experimental Pathology at Memorial Sloan Kettering Cancer Center where I leveraged my expertise to bridge academic medical research with biotechnology and pharmaceutical industries. I have also served on numerous scientific advisory boards, on the Board of Directors for Grupo Oncoclínicas, and as a consultant for multiple biotech companies and Goldman Sachs Merchant Banking. In these roles, I shaped healthcare, healthtech, biotech, and big data strategies designed with the aim of transforming cancer diagnosis and treatment through omics technologies and computational pathology approaches. My experience further includes senior editorial responsibilities at leading journals, including The Journal of the National Cancer Institute, The Journal of Pathology, and npj Breast Cancer.
I have a passion about nurturing the next generation of scientists and promoting diversity within the scientific community. Throughout my career, I have collaborated with talented individuals from diverse backgrounds, united by a shared commitment to harnessing science for positive change.
My work surrounds the intersection of artificial intelligence and data science with the aim to drive therapeutic progress that has the potential to meaningfully improve patient outcomes.
2025
2024
2023
2010
CURRENT ROLE
¶
2025
2023-2025
2012 – 2023
2016 – 2023
2010 – 2012
2006 – 2012
Career highlights
2005
2017
2019
2021
Featured publications
Chromothripsis-mediated small cell lung carcinoma
Rekhtman N, Tischfield SE, Febres-Aldana CA, Lee JJ, Chang JC, Herzberg BO, Selenica P, Woo HJ, Vanderbilt CM, Yang SR, Xu F, Bowman AS, da Silva EM, Noronha AM, Mandelker DL, Mehine M, Mukherjee S, Blanco-Heredia J, Orgera JJ, Nanjangud GJ, Baine MK, Aly RG, Sauter JL, Travis WD, Savari O, Moreira AL, Falcon CJ, Bodd FM, Wilson CE, Sienty JV, Manoj P, Sridhar H, Wang L, Choudhury NJ, Offin M, Yu HA, Quintanal-Villalonga A, Berger MF, Ladanyi M, Donoghue MTA, Reis-Filho JS, Rudin CM. Cancer Discov. 2024 Aug 26. doi: 10.1158/2159-8290.CD-24-0286. Online ahead of print.PMID: 39185963.
Regression-based Deep-Learning predicts molecular biomarkers from pathology slides
El Nahhas OSM, Loeffler CML, Carrero ZI, van Treeck M, Kolbinger FR, Hewitt KJ, Muti HS, Graziani M, Zeng Q, Calderaro J, Ortiz-Brüchle N, Yuan T, Hoffmeister M, Brenner H, Brobeil A, Reis-Filho JS, Kather JN. Nat Commun. 2024 Feb 10;15(1):1253.
Cancer-Causative Mutations Occurring in Early Embryogenesis
Pareja F, Ptashkin RN, Brown DN, Derakhshan F, Selenica P, da Silva EM, Gazzo AM, Da Cruz Paula A, Breen K, Shen R, Marra A, Zehir A, Benayed R, Berger MF, Ceyhan-Birsoy O, Jairam S, Sheehan M, Patel U, Kemel Y, Casanova-Murphy J, Schwartz CJ, Vahdatinia M, Comen E, Borsu L, Pei X, Riaz N, Abramson DH, Weigelt B, Walsh MF, Hadjantonakis AK, Ladanyi M, Offit K, Stadler ZK, Robson ME, Reis-Filho JS, Mandelker D. Cancer Discov. 2022 Apr 1;12(4):949-957.
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
Razavi P, Li BT, Brown DN, Jung B, Hubbell E, Shen R, Abida W, Juluru K, De Bruijn I, Hou C, Venn O, Lim R, Anand A, Maddala T, Gnerre S, Vijaya Satya R, Liu Q, Shen L, Eattock N, Yue J, Blocker AW, Lee M, Sehnert A, Xu H, Hall MP, Santiago-Zayas A, Novotny WF, Isbell JM, Rusch VW, Plitas G, Heerdt AS, Ladanyi M, Hyman DM, Jones DR, Morrow M, Riely GJ, Scher HI, Rudin CM, Robson ME, Diaz LA Jr, Solit DB, Aravanis AM, Reis-Filho JS. Nat Med. 2019 Dec;25(12):1928-1937.
Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors
Pareja F, Brandes AH, Basili T, Selenica P, Geyer FC, Fan D, Da Cruz Paula A, Kumar R, Brown DN, Gularte-Mérida R, Alemar B, Bi R, Lim RS, de Bruijn I, Fujisawa S, Gardner R, Feng E, Li A, da Silva EM, Lozada JR, Blecua P, Cohen-Gould L, Jungbluth AA, Rakha EA, Ellis IO, Edelweiss MIA, Palazzo J, Norton L, Hollmann T, Edelweiss M, Rubin BP, Weigelt B, Reis-Filho JS. Nat Commun. 2018 Aug 30;9(1):3533.
Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples
Martelotto LG, Baslan T, Kendall J, Geyer FC, Burke KA, Spraggon L, Piscuoglio S, Chadalavada K, Nanjangud G, Ng CK, Moody P, D'Italia S, Rodgers L, Cox H, da Cruz Paula A, Stepansky A, Schizas M, Wen HY, King TA, Norton L, Weigelt B, Hicks JB, Reis-Filho JS. Nat Med. 2017 Mar;23(3):376-385.
Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands
Weinreb I, Piscuoglio S, Martelotto LG, Waggott D, Ng CK, Perez-Ordonez B, Harding NJ, Alfaro J, Chu KC, Viale A, Fusco N, da Cruz Paula A, Marchio C, Sakr RA, Lim R, Thompson LD, Chiosea SI, Seethala RR, Skalova A, Stelow EB, Fonseca I, Assaad A, How C, Wang J, de Borja R, Chan-Seng-Yue M, Howlett CJ, Nichols AC, Wen YH, Katabi N, Buchner N, Mullen L, Kislinger T, Wouters BG, Liu FF, Norton L, McPherson JD, Rubin BP, Clarke BA, Weigelt B, Boutros PC, Reis-Filho JS. Nat Genet. 2014 Nov;46(11):1166-9.
Triple-negative breast cancer
Foulkes WD, Smith IE, Reis-Filho JS. N Engl J Med. 2010 Nov 11;363(20):1938-48.
Breast cancer molecular profiling with single sample predictors: a retrospective analysis
Weigelt B, Mackay A, A'hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS. Lancet Oncol. 2010 Apr;11(4):339-49.
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A. Nature. 2008 Feb 28;451(7182):1111-5.
Veeva ID: Z4-81204
Date of preparation: February 2026